Finished product reference
Ipratropium Bromide / Fenoterol Hydrobromide
Aerosol, Metered · Respiratory · 20 µg/50 µg/1 dose · 200 dose
- List code
- 17611
- Pharmacologic class
- Bronchodilator combination; short-acting antimuscarinic plus short-acting beta2-agonist
What it is and how it works
Ipratropium bromide is an antimuscarinic that blocks acetylcholine-induced bronchoconstriction mediated by vagal pathways. Fenoterol hydrobromide stimulates beta2-adrenoceptors, relaxing bronchial smooth muscle. The two mechanisms are complementary, giving a greater bronchodilator effect than either alone.
Indications
Prevention and treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease and asthma.
Dosage and administration (summary)
By metered-dose inhalation, usually 1–2 puffs (ipratropium 20 micrograms/fenoterol 50 micrograms per puff) up to 3–4 times daily, with up to 8 puffs in 24 hours; acute bronchospasm may require additional puffs as directed.
Contraindications
Hypertrophic obstructive cardiomyopathy, tachyarrhythmia, and hypersensitivity to fenoterol, ipratropium or atropine-like substances.
Warnings and precautions
Caution in uncontrolled diabetes, recent myocardial infarction, severe cardiac or vascular disease, hyperthyroidism, phaeochromocytoma, narrow-angle glaucoma (avoid contact with eyes) and urinary outflow obstruction. Beta2-agonists can cause serious hypokalaemia, tachycardia and paradoxical bronchospasm; increasing use indicates worsening disease requiring review, and asthma patients should also receive anti-inflammatory therapy.
Pregnancy
Use with caution, particularly in the first trimester and near term, as fenoterol may inhibit uterine contractions.
Storage and supply
Store below 25 °C; protect from heat and direct sunlight; do not puncture or burn the canister even when empty.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.